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Abstract
Background: The incidence of classical Hodgkin lymphoma (cHL) and its association with Epstein-Barr virus (EBV) varies
significantly with age, sex, ethnicity and geographic location. This is the first report on epidemiological features of cHL
patients from Northern regions of China. These features are compared to data from a previously published Dutch cHL
population.
Methodology/Principal Findings: 157 cHL patients diagnosed between 1997 and 2008 in the North of China were included
after histopathological re-evaluation. The Dutch population-based cohort consisted of 515 cHL patients diagnosed between
1987 and 2000. EBV status was determined by in situ hybridization of EBV- encoded small RNAs. In the Chinese population,
tumor cells of 39% of the cHL patients were EBV+ and this was significantly associated with male sex, mixed cellularity
subtype and young age (,20 y). The median age of the Chinese patients was 9 years younger than that of the Dutch
patients (28 y vs. 37 y). In addition, the age distribution between the two populations was strikingly different in both the
EBV+ subgroups (p,0.001) and the EBV- subgroups (p=0.01). The mixed cellularity subtype was almost 3x more frequent
amongst the Chinese (p,0.001).
Conclusion/Significance: CHL patients from Northern regions of China show a distinctive age distribution pattern with a
striking incidence peak of EBV+ mixed cellularity cases among children and adolescents and another high incidence peak of
EBV- nodular sclerosis cases in young adults. In comparison to Dutch cHL patients there are pronounced differences in age
distribution, subtype and EBV status, presumably caused by complex gene-environmental interactions.
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Introduction
Classical Hodgkin lymphoma (cHL) is a heterogeneous
malignancy with a complex etiology and epidemiology. In general,
cHL accounts for about 1% of all cancers and ,30% of the
lymphoid malignancies worldwide [1]. Epidemiologic studies of
cHL demonstrate a remarkable diversity of the incidence
according to age, sex, ethnic background, geographic location
and socioeconomic status [2,3]. The highest incidence was
reported among Caucasians, followed by African Americans and
Hispanics, and the lowest incidence was found in Orientals [3].
Data from the International Agency for Research on Cancer
(http://globocan.iarc.fr/) shows a nearly 6-fold difference between
Western Europe and East Asia with an incidence of 2.3 and 0.4
per 100,000 inhabitants per year respectively in 2008. A genetic
explanation for this difference has been shown in a multi-ethnic
study of cHL in the United States that reported the lowest
incidence rate in Asian immigrants in comparison to other ethnic
origins [4]. However, a trend of increasing incidence of cHL was
reported among Chinese immigrants in western countries [4,5],
suggesting an influence of westernization. The incidence pattern
by age was also shown to be different between Caucasian and
Oriental populations [6,7]. Western populations typically have a
bimodal age distribution with two peaks near 25 and 60 ys. In
Orientals, a first incidence peak usually presents in childhood with
a second peak in the elderly, although in Japanese cHL patients
the early incidence peak was reported to be absent [4,8].
Epstein-Barr virus (EBV) is present in the tumor cells in a
proportion of patients and EBV is accepted as a causal agent in
these patients [7,9]. There is a striking variability in the percentage
of EBV involved cases between racial groups and geographic
locations [2,10]. The proportion of EBV involvement is almost
100% in Hispanic cHL patients [11], much lower in Caucasians
(20,40%) [2,12] and intermediate in Orientals [13,14]. In
general, the EBV association with cHL is related to age, being
the strongest in children and the elderly [15,16]. In addition, male
sex and the mixed cellularity (MC) histological subtype are
associated with EBV+ cHL worldwide [15,17].
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ological characteristics of cHL patients from Northern China. In
addition, these characteristics were compared to data from a
previously reported Dutch cHL patient population [18].
Materials and Methods
Patient selection and data collection
157 cHL patients were included in this study [19]. These
patients resided in the Northern area of China and were diagnosed
with cHL during the period of 1997 to 2008 at the Dept. of
Pathology, Health Science Center, Peking University (n=78),
Zhanye Regional Hospital, Gansu Province (n=22), First Hospital
of Jilin University (n=14), Beijing Air Army General Hospital
(n=14), Shougang Hospital, Peking University (n=13) and a
number of other smaller hospitals (1 to 3 patients per hospital;
n=16). For all patients we retrieved the original data from the
pathology database, including histological subtype, patients’ sex
and age at the time of diagnosis. Ethical approval for this study
was not required by these institutions as the experiments carried
out did not relate to patients privacy or treatment. Research was
conducted adhering to the Declaration of Helsinki and according
to Dutch regulations (http://www.federa.org/). The institutional
review board (the Medical Ethics Review Board of the University
Medical Center Groningen) specifically waived the needs for ethics
approval and consent.
Histopathological re-evaluation
Formalin fixed paraffin embedded tissue blocks from 157
patients were available and were used to cut slides for
haematoxylin and eosin staining and for determining EBV status.
Histological re-evaluation was done according to the most recent
WHO classification system [1] which categorizes cHL into four
histological subgroups, i.e. nodular sclerosis (NS), mixed cellularity
(MC), lymphocyte rich (LR) and lymphocyte depletion (LD). Cases
without enough tissue for proper evaluation of the background
Table 1. Distribution of age, sex and histology by EBV status in Chinese cHL patients.
all patients EBV+ EBV- EBV+ vs. EBV-
n=157 n=62 n=95 p-value
n% n% n%
sex
male 101 64 47 76 54 57 0.015*
female 56 36 15 24 41 43
histological subtype
NS 78 61 12 25 66 82 ,0.001
{
MC 46 36 34 71 12 15
L R 43 24 23
NOS 29 14 15
median age (range) 28 (4–74) 31 (4–74) 28 (8–74) n.s.
{
*Chi square test,
{ Fisher’s exact test, NOS cases were excluded,
{ Mann Whitney U test, NS indicates nodular sclerosis; MC, mixed cellularity; LR, lymphocyte rich; LD
lymphocyte depletion; NOS, not otherwise specified; n.s., not significant.
doi:10.1371/journal.pone.0021152.t001
Table 2. Distribution of age, sex and histology by EBV status in Dutch cHL patients.
all patients EBV+ EBV- EBV+ vs. EBV-
n=515 n=181 n=334 p-value
n% n% n%
sex
male 298 58 118 65 180 54 0.013*
female 217 42 63 35 154 46
histological subtype
NS 413 83 114 66 299 92 ,0.001
{
MC 63 13 48 28 15 4
LR 12 2 3 2 9 3
L D 92 74 21
NOS 18 9 9
median age (range) 37 (8–94) 43 (8–94) 34 (9–90) ,0.001
{
*Chi square test,
{ Fisher’s exact test, NOS cases were excluded,
{ Mann Whitney U test, NS indicates nodular sclerosis; MC, mixed cellularity; LR, lymphocyte rich; LD
lymphocyte depletion; NOS, not otherwise specified.
doi:10.1371/journal.pone.0021152.t002
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(NOS).
EBV status
Presence of EBV in tumor cells was determined by EBER in situ
hybridization (ISH) with a fluorescein-conjugated PNA probe
specific for the EBV-encoded EBER RNAs (DAKO, Glostrup,
Denmark) using standard laboratory protocols. Appropriate
positive and negative controls were included in all analyses.
Statistical analysis
Differences between EBV+ and EBV- groups in relation to age,
sex and histopathological subtype were assessed by Chi square test,
Fisher’s exact test or Mann Whitney U test. The data were
analyzed with SPSS for Windows, version 17.0. A p-value ,0.05
was considered significant.
Results
Histopathological re-evaluation and EBV status
The 157 cHL cases were re-evaluated for histological subtype.
The subtype could not be unequivocally determined in 29 (18%)
cases and was designated cHL-NOS. Six and 9 of these cases were
previously classified as LR and MC subtype respectively.
Discrepancies in the classification were observed in 5 out of 13
LR cases and 6 out of 57 MC cases which were reclassified as MC
and NS subtype respectively. All original NS diagnoses were re-
evaluated as NS subtype. A consistent classification was achieved
for 117 of 128 (91.4%) cHL cases.
NS was the most common subtype in the Chinese patient
population, accounting for 61% of cases (n=78), followed by MC
with 36% (n=46) and LR with 3% (n=4) of cases. The
lymphocyte depleted subtype was not represented. EBER ISH
was positive in 39% of Chinese cHL patients (n=62; Table 1).
Distribution of age, sex and histological subtypes
The male to female ratio was 1.8 in the total group, 3.1 in the
EBV+ group and 1.3 in the EBV- group (p=0.015). The MC
subtype was more common in EBV+ cHL patients (71%) and the
NS subtype was more common in the EBV- group (82%)
(p,0.001). Although the median age of cHL patients in the
EBV+ group did not differ much from that of the EBV- cHL
patient group (31 years, range: 4–74 ys and 27 years, range: 8–
74 ys respectively) (Table 1), the 10 years age group distribution
between EBV+ and EBV- patients did show a highly significant
difference (p,0.001). Patients in the age groups from 0 to 10 were
significantly more often EBV+ (p=0.003), while patients aged 21
to 30 were significantly more often EBV- (p,0.001).
Comparison between Chinese and Dutch cHL patients
Characteristics of the Dutch cHL population were consistent
with the epidemiology of cHL in Western Europe (Table 2). There
was a small difference in the sex distribution between Dutch and
Chinese cHL patients with a male to female ratio of 1.8 in the
Chinese and 1.4 in the Dutch population. In the EBV+ group
males were overrepresented in the Chinese as compared to the
Dutch population (male to female ratio of 3.1 vs. 1.8); however,
these differences were not significant. In the EBV- group the
Chinese male to female ratio was comparable to the Dutch (1.3 vs.
1.2).
In the Chinese patients, the MC subtype was much more
frequent than in the Dutch patients (36% vs. 13%) (p,0.001)
(Table 3). In both populations the MC subtype was highly and
equally associated with EBV positivity (Chinese 74% vs. Dutch
76%). The NS subtype was less often EBV associated in the
Chinese as compared to the Dutch cHL patients (15% vs. 28%)
(p=0.024).
The median age of Chinese patients (28 ys, range: 4–74 ys) was
9 years younger than that of the Dutch population (37 ys, range:
8–94 ys) (p,0.001) and the age distribution in 10-year intervals
was significantly different (p,0.001) (Figure 1, Table 4). Similar to
the Chinese patients, stratification by EBV status showed
significant differences in median age between EBV+ (43 ys, range:
8–94) and EBV- (33 ys, range: 9–90) Dutch cHL patients
(p,0.001). Comparison of the EBV+ Chinese patient group with
the EBV+ Dutch patient group showed a striking difference in the
age distribution (p,0.001) (Figure 2A, Table 4). In young Chinese
patients (younger than 16 years), there was a high number of MC
subtype (14 out of 20) and all of these MC cases were EBV
associated (Table 3). In addition, the age distribution of the EBV-
Chinese patients was significantly different from the EBV- Dutch
patients (p=0.01) (Figure 2B, Table 4).
Discussion
Epidemiological cHL studies have shown significant variations
in age and EBV positivity in relation to ethnic background and
geographic location. Asians are known to have the lowest
incidence of cHL and an intermediate level of EBV association
[3]. Previously, a few studies reported on cHL epidemiology in
Table 3. Differences in subtype distribution in Chinese and
Dutch cHL patients.
Chinese Dutch
n % n % p-value
all patients 157 515 .
NS 78 61 413 83 ,0.001*
MC 46 36 63 13
L R 431 2 2
L D 009 2
NOS 29 18
all EBV+ patients 62 181
NS 12 25 114 66 ,0.001*
MC 34 71 48 28
L R 243 2
L D 007 4
NOS 14 9
young patients (4–15 ys)
NS 5 25 21 95 ,0.001
{
MC 14 70 1 5
L R 150 0
NOS 4 1
young EBV+ (4–15 ys)
NS 3 18 8 89 ,0.001
{
MC 14 82 1 11
L R 000 0
NOS 4 1
*Chi square and
{ Fisher’s exact test for NS and MC; NS indicates nodular
sclerosis; MC, mixed cellularity; LR, lymphocyte rich; LD lymphocyte depletion;
NOS, not otherwise specified.
doi:10.1371/journal.pone.0021152.t003
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the Southern Chinese population [13,20–22]. Importantly, the
Northern Chinese population is genetically different from the
Southern Chinese population, especially in the distribution of
Human Leukocyte Antigen (HLA) types. Undifferentiated naso-
pharyngeal carcinoma (UNPC), another EBV-associated malig-
nancy with a latent EBV expression pattern similar to EBV+ cHL,
is endemic in Southern China but not in Northern China.
Previous studies have proposed that geographic differences in the
allele frequency of the UNPC susceptibility allele HLA-A*02:07
might well explain the high incidence of UNPC in the Southern
Chinese population. Thus, differences in cHL incidence and EBV
association might also be expected in different Chinese regions.
The main aim of this study was to analyze the epidemiology of
cHL in patients from the Northern part of China, a population
that has not been studied before.
Previous studies found a relatively high level of EBV
association in cHL patients from Hong Kong (65%, n=23,
EBER ISH), China (61%, n=28, EBER ISH) and Taiwan
(63%, n=70, EBER ISH and LMP1 immunohistochemistry
combined) [13,14,21]. These frequencies are higher than the
39% of EBV positivity identified in the present patient cohort
(n=157). Besides the population size, differences in EBV
prevalence might also be influenced by intra-ethnic environ-
mental and genetic variations. Consistent with previous findings
in Chinese and other ethnic groups of cHL patients, the
incidence of EBV+ cHL was significantly higher in males and
the MC subtype [2].
A shift in the histological classification upon histopathological
re-examination was observed in 8.6% (n=11) of the cases, partly
explained by changes in the WHO classification guidelines.
Agreement was specifically poor for the LR and MC subtypes.
Due to the lack of enough tissue for evaluating the background
architecture, 15 cases previously diagnosed as LR or MC subtype
were re-assigned as cHL-NOS. Overall, the histological distribu-
tion was similar to those reported in previous Chinese populations
from Hong Kong and Taiwan [13,23].
Until now, there are four studies that investigated the age
distribution of cHL in the Chinese population [13,20–22]. Three
studies, including two from Hong Kong (n=23 and n=92)
[13,20] and another one from Taiwan (n=70) [21], identified a
bimodal age distribution with two peaks at the second and sixth
decades respectively, whereas another study from Taiwan (n=42)
[22] found a single age peak at the 3rd decade. Consistent with this
last study, we also found a unimodal age distribution with a
distinctive peak incidence occurring at the 3rd decade. Only two
of the four studies (Hong Kong and Taiwan) included EBV status
into the analyses [13,21]. Our results were consistent with these
studies for EBV- cHL patients with a single incidence peak in
Figure 1. Age distribution of Dutch and Chinese cHL patients in consecutive 10-year intervals. Age distribution is shown for 157 patients
from Northern regions of China (black) and 515 patients from the Northern part of the Netherlands (grey). The two curves exhibit a somewhat similar
trend with significant differences at the first, second, eighth and ninth decade (*=p,0.01, **=p,0.001) between the Chinese and the Dutch
population (6% vs. 1%, 22% vs. 12%, 1% vs. 7% and 0% vs. 3% respectively). The Chinese population has more patients among the first three decades
as compared to the Dutch population, both having the highest peak in the third decade. The Chinese population does not show a second incidence
peak at around 60 years.
doi:10.1371/journal.pone.0021152.g001
Table 4. Differences in age distribution in Chinese and Dutch
cHL patients.
Chinese Dutch
n age n age p-value*
median range median range
all patients 157 28 4–74 515 37 8–94 ,0.001
EBV2 95 28 8–74 334 34 9–90 0.01
EBV+ 62 31 4–74 181 43 8–94 ,0.001
*Mann Whitney U test.
doi:10.1371/journal.pone.0021152.t004
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incidence peak in the elderly, in contrast to both other studies.
Comparison of the Chinese and Dutch cHL patient groups
revealed a significant inter-ethnic difference in the age distribution
in the total populations and also in the EBV+ and EBV- subgroups
separately. A bimodal pattern for the age distribution of cHL in
general as well as in the EBV+ subgroup is considered typical for
the Western population and this was also present in our Dutch
cohort. It has been reported that in the Asian cHL population, an
early peak should be less obvious and at a younger age compared
to the Western population, whereas a second peak at older age
should be similar [4,8]. Intriguingly, our Chinese population had
an evident early peak similar to the Dutch population but lacked
the peak at older age. The relative lack of elderly patients in our
study might partially be explained by a lower life expectancy in
China as compared to the Netherlands. In addition, there might
be a bias of elderly patients being diagnosed in smaller, rural
hospitals that were not included in this study. It is unclear whether
these potential effects could have affected an incidence peak in the
61 to 70 years age group.
Figure 2. Age distribution of Dutch and Chinese cHL patients stratified by EBV status. A represents the comparison of the age distribution
in the two EBV+ cHL subpopulations. Chinese EBV+ cHL patients (black) exhibited a significant single peak in the first and second decade with a
maximum percentage of 26% (*=p,0.01). In contrast, Dutch EBV+ cHL patients (grey) demonstrated a clear bimodal age distribution pattern with
two peaks occurring in the third and seventh decade respectively with a similar incidence for both peaks (17% and 18%). B shows the age distribution
curve of the EBV- cHL patients. There is a single incidence peak in the third decade for both populations, which is more pronounced in the Chinese
population (39% vs. 27%).
doi:10.1371/journal.pone.0021152.g002
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age distribution as EBV- Asian cHL. However, in the present
study EBV+ cHL had a different and pronounced incidence peak
at adolescence and was strongly associated with the MC subtype.
This incidence peak of EBV+ cHL at young age closely resembles
that seen in various developing regions in the world, including
South America, Mexico and the Middle East and is associated
with a low socioeconomic status and early exposure to EBV [24–
30]. In both the Chinese and the Dutch populations a clear peak
for EBV- NS patients was observed at the 3rd decade. This peak
was higher in the Chinese population than in the Dutch
population (39% vs. 27%), which is surprising because this peak
has been associated with developed, industrialized populations
[31]. Thus, the epidemiology of our cHL patient cohort from the
Northern part of China shows characteristics of both a developing
and a well-developed population.
In conclusion, we demonstrate a distinctive age distribution
pattern in a large group of Northern Chinese cHL patients with a
striking incidence peak among young adults. Moreover, we
identified large inter-ethnic differences in the distribution of age,
EBV status and histological subtype in comparison to a Caucasian
population. Both genetic and environmental factors are expected
to play a role in these differences.
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